Concepedia

Author

Anne Dekeyne

AVL (France)

Also Known As

A DEKEYNE, A Dekeyne, A. Dekeyne, Anne Dekeyne

92

Publications

3.6K

Citations

34

H-Index

57

Concepts

All Affiliations

AVL (France)Servier (France)Centre National de la Recherche Scientifique
AD

About

Anne Dekeyne is an author at AVL (France) specializing in medicine, neuropharmacology, and neuroscience.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

30

1.7K

2

Social Sciences

20

28

1.5K

3

Health Sciences

2

2

59

4

Behavioral Sciences

2

2

98

5

Natural Sciences

1

1

30

Anne Dekeyne

×

54

Publications

3.5K

Citations

33

H-Index

YearCitations

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

Mark J. Millan, Anne Dekeyne, Alain P. Gobert

Neuropharmacology

1998

282

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

Mark J. Millan, Mauricette Brocco, Alain P. Gobert,

Psychopharmacology

2004

244

Agonist and antagonist actions of yohimbine as compared to fluparoxan at ?2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states

Mark J. Millan, Adrian Newman‐Tancredi, Val�rie Audinot,

Synapse

2000

191

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α<sub>2</sub>‐adrenergic and serotonin<sub>2C</sub> receptors: a comparison with citalopram

Mark J. Millan, Alain P. Gobert, Jean‐Michel Rivet,

European Journal of Neuroscience

2000

167

5‐HT <sub>6</sub> receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia

Julie Meffre, Séverine Chaumont‐Dubel, Clotilde Mannoury la Cour,

EMBO Molecular Medicine

2012

162

A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194

Valérie Audinot, Adrian Newman‐Tancredi, Alain P. Gobert,

Journal of Pharmacology and Experimental Therapeutics

1998

128

Selective blockade of dopamine D<sub>3</sub>versus D<sub>2</sub>receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis

Mark J. Millan, Benjamin Di Cara, Anne Dekeyne,

Journal of Neurochemistry

2006

124

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

Anne Dekeyne, Clotilde Mannoury la Cour, Alain P. Gobert,

Psychopharmacology

2008

124

S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: II. Functional and Behavioral Profile Compared with GR218,231 and L741,626

Mark J. Millan, Anne Dekeyne, Jean‐Michel Rivet,

Journal of Pharmacology and Experimental Therapeutics

2000

120

S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: II. Behavioral Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine

Mark J. Millan, Anne Dekeyne, Mariusz Papp,

Journal of Pharmacology and Experimental Therapeutics

2001

116

Page 1